| |
| |
|
| Insider
Information: |
Sharp Shalini |
| Relationship: |
Director |
| City: |
New York |
| State: |
NY |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
5 |
|
| Direct
Shares |
215,117 |
|
|
Indirect Shares
|
104,270 |
|
|
| Direct
Value |
$4,535,908 |
|
|
|
Indirect Value
|
$46,244 |
|
|
| Total
Shares |
319,387 |
|
|
| Total
Value |
$4,582,151 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
6
|
|
Stock
price went up :
|
0
|
5
|
| Stock
price went down : |
0
|
1
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
5.0
|
| Percentage
Gain/Loss : |
0.0%
|
 537.9%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Agenus Inc |
AGEN |
Director |
2013-01-30 |
81,311 |
2015-09-28 |
104,270 |
Premium* |
|
|
Ultragenyx Pharmaceutical Inc |
RARE |
EVP, Finance |
2020-10-14 |
97,812 |
|
0 |
Premium* |
|
|
Nuvation Bio Ord Shs Class A |
NUVB |
Director |
2021-02-10 |
35,000 |
2021-02-10 |
0 |
Premium* |
|
|
Mirati Therapeutics, Inc. |
MRTX |
|
2024-01-23 |
0 |
2021-03-26 |
0 |
Premium* |
|
|
Neurocrine Biosciences Inc |
NBIX |
Director |
2024-05-17 |
994 |
2024-05-17 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
130 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 4 of 6
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| AGEN |
Agenus Inc |
CFO |
• – – |
2012-03-15 |
4 |
A |
$5.31 |
$25,817 |
D/D |
4,862 |
69,252 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2007-03-12 |
4 |
B |
$1.95 |
$9,736 |
D/D |
5,000 |
14,579 |
2.74 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2007-03-13 |
4 |
B |
$1.97 |
$9,836 |
D/D |
5,000 |
19,579 |
2.74 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2009-09-10 |
4 |
A |
$2.40 |
$12,000 |
D/D |
5,000 |
164,495 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2010-09-10 |
4 |
A |
$0.93 |
$4,650 |
D/D |
5,000 |
246,098 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2011-09-12 |
4 |
A |
$0.55 |
$2,750 |
D/D |
5,000 |
306,079 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
5,634 |
106,157 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2016-12-23 |
4 |
OE |
$0.81 |
$5,265 |
D/D |
6,500 |
51,887 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2018-05-30 |
4 |
OE |
$0.82 |
$5,298 |
D/D |
6,500 |
70,174 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2018-06-07 |
4 |
AS |
$80.07 |
$536,456 |
D/D |
(6,700) |
53,478 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2018-09-25 |
4 |
AS |
$90.07 |
$603,469 |
D/D |
(6,700) |
50,128 |
0 |
- |
|
| MRTX |
Mirati Therapeutics, Inc. |
Director |
– • – |
2023-12-29 |
4 |
A |
$58.75 |
$399,970 |
D/D |
6,808 |
16,222 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2018-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
7,000 |
62,510 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-05-19 |
4 |
OE |
$48.43 |
$431,710 |
D/D |
7,128 |
104,851 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-05-19 |
4 |
S |
$73.32 |
$522,625 |
D/D |
(7,128) |
101,556 |
0 |
% |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2008-01-07 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
28,022 |
0 |
- |
|
| AGEN |
Agenus Inc |
CFO |
• – – |
2009-01-05 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
63,890 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
70,137 |
0 |
- |
|
| NUVB |
Nuvation Bio Ord Shs Clas... |
Director |
– • – |
2021-02-10 |
4 |
A |
$10.00 |
$100,000 |
D/D |
10,000 |
35,000 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-06-03 |
4 |
OE |
$48.43 |
$495,633 |
D/D |
10,234 |
111,442 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-06-03 |
4 |
S |
$74.23 |
$759,670 |
D/D |
(10,234) |
101,208 |
0 |
% |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Executive Vice President |
• – – |
2020-08-17 |
4 |
OE |
$48.43 |
$698,524 |
D/D |
11,357 |
101,856 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2015-12-10 |
4 |
AS |
$101.03 |
$1,219,957 |
D/D |
(12,000) |
41,801 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2015-12-10 |
4 |
OE |
$0.82 |
$9,780 |
D/D |
12,000 |
53,801 |
0 |
- |
|
| RARE |
Ultragenyx Pharmaceutical... |
CFO & Senior Vice President |
• – – |
2016-10-19 |
4 |
AS |
$60.98 |
$736,820 |
D/D |
(12,000) |
45,387 |
0 |
- |
|
130 Records found
|
|
Page 4 of 6 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
